Plasma growth differentiation factor - 8 / Myostatin level as prognostic biomarker of patients with ischemic stroke and acute revascularization therapy. PARADISE study.

Fiche publication

Date publication

mars 2023

Journal

Journal of the neurological sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGELY Catherine

Tous les auteurs :
Jakubina P, Meloux A, Duloquin G, Aho S, Vergely C, Béjot Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36958132

Résumé

Identifying biological markers of ischemic stroke (IS) is an important research approach to develop innovative therapeutic strategies. This study aimed to assess the association between plasma Growth Differentiation Factor-8 (GDF-8)/Myostatin levels and outcome of IS patients.